Phio Pharmaceuticals Business Summary

Phio Pharmaceuticals Corp. (PHIO) is a clinical-stage biotechnology company that operates primarily through the development of immuno-oncology therapeutics using its proprietary INTASYL® self-delivering RNAi technology platform. The company generates revenue through strategic licensing agreements, research grants, and capital market transactions, as it currently lacks commercialized products and remains in the clinical-development phase. Its business model is centered on the discovery and advancement of siRNA-based compounds, such as lead candidate PH-762 for skin cancers and PH-894 for various solid tumors, which are designed to silence immunosuppressive genes without the need for complex delivery vehicles like lipid nanoparticles. Phio competes directly with established RNAi players such as Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals, as well as immunotherapy-focused firms like NextCure. Within this landscape, Phio occupies a high-specialization niche by leveraging its "self-delivering" chemical modifications to simplify drug administration and reduce systemic toxicity compared to traditional delivery-dependent peers. The company was co-founded by Nobel Laureate Dr. Craig Mello, who received the 2006 Nobel Prize for the discovery of RNA interference. The current leadership team is headed by President and CEO Robert J. Bitterman, who also serves as Chairman and previously led Cutanea Life Sciences to its acquisition by Biofrontera. Recent executive realignments as of February 2026 include the promotion of Lisa Carson to Chief Financial Officer, formerly of Prelude Therapeutics, and Jennifer Phillips, Pharm.D., to Senior Vice President of Regulatory and Corporate Affairs. The operational team is further bolstered by Kimberly Man, Vice President of Program Development, and Linda Mahoney, SVP of Development. Governance is overseen by a board that includes Lead Independent Director David H. Deming, a former JP Morgan Managing Director, with institutional backing from major shareholders such as Geode Capital Management, Virtu Financial, and Vanguard Fiduciary Trust Co.